Meiji Seika Pharma Co., Ltd. reported that Adcock Ingram Pharma, an affiliated company of Medreich Ltd., completed construction of a new manufacturing facility in Bengaluru, India, to expand production capacity for its contract manufacturing organization (CMO) business.

Adcock Ingram is a wholly owned subsidiary of Adcock Ingram Limited, a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Limited.

The new manufacturing facility has three floors with a total floor area of 7,878 square meters, and an annual production capacity of 750 million tablets, 75 million sachets, and four million bottles.

The aim is for Adcock Ingram to manufacture and supply pharmaceutical products not only for the Adcock Ingram Group in South Africa, but also for other clients.

The Meiji Group’s Pharmaceutical Segment, in its “2023 Medium-Term Business Plan”, has set an agenda to expand its CMO/CDMO business.

In a statement, the company said that it will continue to optimize its production bases in Japan and overseas, strengthen its production system and establish a stable supply of highly reliable pharmaceuticals as well as contribute to improving access to pharmaceuticals.